Drug Trial Radar · NCT03788967
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Last checked: Nov 19, 2026Latest source record: Jul 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,372
Actual
Start
Jun 3, 2019
Primary completion
May 20, 2020
Study completion May 27, 2020
Sponsor
- Lead sponsor
- Spero TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The key purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) compared to intravenous (IV) ertapenem, in participants with complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP).
Conditions
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
Interventions
TBPM-PI-HBrDrug
TBPM-PI-HBr tablets administered orally.
ErtapenemDrug
Antibiotic Therapy for cUTI.
Dummy InfusionDrug
Dummy intravenous infusion.
Dummy tabletsDrug
Dummy tablets orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat PopulationTime frame: Day 19 (TOC)
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety PopulationTime frame: From the first dose of administration up to Day 25 post-treatment ± 2 days (up to approximately 27 days)
Locations
96 sites in 15 countries. Site status is shown where the registry gives one.
Medical Facility
La Mesa, California
Medical Facility
Miami, Florida
Medical Facility
Blagoevgrad, Bulgaria
Medical Facility
Dobrich, Bulgaria
Medical Facility
Rousse, Bulgaria
Medical Facility
Shumen, Bulgaria
Medical Facility
Sofia, Bulgaria
Medical Facility
Sofia, Bulgaria
Medical Facility
Veliko Tarnovo, Bulgaria
Medical Facility
Karlovy Vary, Czechia
Medical Facility
Liberec, Czechia
Medical Facility
Prague, Czechia
Medical Facility
Ústí nad Labem, Czechia
Medical Facility
Zlín, Czechia
Medical Facility
Kohtla-Järve, Estonia
Medical Facility
Tallinn, Estonia
Medical Facility
Võru, Estonia
Medical Facility
Tbilisi, Georgia
Medical Facility
Tbilisi, Georgia
Medical Facility
Tbilisi, Georgia
Medical Facility
Tbilisi, Georgia
Medical Facility
Zestaponi, Georgia
Medical Facility
Budapest, Hungary
Medical Facility
Budapest, Hungary
Medical Facility
Nagykanizsa, Hungary
Medical Facility
Nyíregyháza, Hungary
Medical Facility
Tatabánya, Hungary
Medical Facility
Riga, Latvia
Medical Facility
Riga, Latvia
Medical Facility
Valmiera, Latvia
Medical Facility
Chisinau, Moldova
Medical Facility
Chisinau, Moldova
Medical Facility
Katowice, Poland
Medical Facility
Krakow, Poland
Medical Facility
Lodz, Poland
Medical Facility
Oświęcim, Poland
Medical Facility
Wroclaw, Poland
Medical Facility
Bucharest, Romania
Medical Facility
Bucharest, Romania
Medical Facility
Bucharest, Romania
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.